Ann: Half Year Financial Results Presentation, page-77

For sure, and evidence points to that being (hopefully successfully negotiated with FDA) an acceptable end point. That's where my hard earned punter money is riding. I guess I was being picky with detailed MOAs and olaying devils advocate a bit, fully aware of the threat from FDA of this fallback argument to block approvals despite efficacy matrix evidence. The "how high is the sky" comeback thrown out from chaise lounge, grapes, pharmacy degree on wall etc

But I also like the "enhance neovascularisation, increase and stabilise capillary networks surrounding cardiomyocytes" etc etc. part of the graphic , an explicit reference to regenerative effect that may be the shape of things to come, (and that may be downplayed prior to approval because of the classic stem cell paradigm and associated... views).
Cheers.